Trump's FDA Vaccine Head Departs for Second Time

WASHINGTON — Dr. Vinay Prasad, head of vaccines at the U.S. Food and Drug Administration (FDA), will depart the agency for the second time in less than a year. FDA Director Marty Makary announced via email on Friday that Prasad would leave at the end of April to return to an academic position at the University of California, San Francisco. This marks Prasad's second departure from the FDA — the previous time in July 2025, he was dismissed and then reinstated less than two weeks later. This latest departure follows a series of major controversies: from the FDA's refusal to review Moderna's mRNA flu vaccine to a public confrontation with UniQure over its gene therapy for Huntington's disease.

The story of Vinay Prasad is not simply about an official leaving office. It is a symptom of severe disarray within the world's largest pharmaceutical regulatory body — with ramifications that could last for years.

Prasad joined the FDA in May 2025 with a reputation as a veteran critic of drug approval standards. He aimed both to accelerate the process and tighten scientific criteria — two conflicting goals that he seemed unable to manage in practice. The result: pharmaceutical companies of all sizes were shocked, investors were confused, and patients with rare diseases were caught in the crossfire.

The rejection of Moderna's mRNA flu vaccine application is a prime example. This was not a decision made through a transparent process — it was leaked, Moderna publicly spoke out, and the FDA was forced to reverse course within a week. This kind of governance undermines trust on both sides: it lacks credibility for the pharmaceutical industry and creates the impression that the FDA is being swayed by lobbying.

The UniQure incident was even stranger. The FDA held a press conference to publicly criticize a product under review — an extremely unusual move in the agency's history. An anonymous FDA official told the press that UniQure's product was a "complete failure." With tens of thousands of Huntington's patients in the US awaiting, such conduct was not only unprofessional but also cruel.

The larger picture: under Secretary of Health Robert F. Kennedy Jr. — who has a long history of vaccine skepticism before

Vietnamese-American healthcare professionals — doctors, pharmacists, nurses — working in US hospitals and clinics will closely monitor this situation. Instability at the FDA directly impacts the drug and vaccine approval processes they use daily in patient treatment. Those specializing in rare diseases or cancer, in particular, will be concerned by the FDA's continuous shifts in decisions regarding gene and biological therapies.

Second-generation Vietnamese Americans working in the biotech and pharmaceutical industries in Silicon Valley or the greater Boston area